2,713 Shares in Hologic, Inc. (NASDAQ:HOLX) Acquired by William Blair Investment Management LLC

William Blair Investment Management LLC bought a new position in shares of Hologic, Inc. (NASDAQ:HOLX) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 2,713 shares of the medical equipment provider’s stock, valued at approximately $212,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Bleakley Financial Group LLC increased its holdings in Hologic by 18.3% during the 1st quarter. Bleakley Financial Group LLC now owns 5,412 shares of the medical equipment provider’s stock valued at $422,000 after purchasing an additional 836 shares in the last quarter. Sei Investments Co. increased its holdings in Hologic by 8.8% during the 1st quarter. Sei Investments Co. now owns 1,422,528 shares of the medical equipment provider’s stock valued at $110,901,000 after purchasing an additional 115,051 shares in the last quarter. New South Capital Management Inc. increased its holdings in Hologic by 0.4% during the 1st quarter. New South Capital Management Inc. now owns 194,519 shares of the medical equipment provider’s stock valued at $15,165,000 after purchasing an additional 750 shares in the last quarter. Forsta AP Fonden increased its holdings in Hologic by 6.5% during the 1st quarter. Forsta AP Fonden now owns 52,800 shares of the medical equipment provider’s stock valued at $4,116,000 after purchasing an additional 3,200 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its holdings in Hologic by 14.9% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 34,547 shares of the medical equipment provider’s stock valued at $2,693,000 after purchasing an additional 4,490 shares in the last quarter. Institutional investors own 94.73% of the company’s stock.

Wall Street Analyst Weigh In

HOLX has been the subject of several research reports. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Friday, May 3rd. Citigroup raised Hologic from a “neutral” rating to a “buy” rating and lifted their target price for the company from $80.00 to $95.00 in a research note on Wednesday, April 3rd. Stephens initiated coverage on Hologic in a research note on Thursday, June 27th. They issued an “overweight” rating and a $87.00 target price for the company. JPMorgan Chase & Co. lifted their target price on Hologic from $85.00 to $91.00 and gave the company an “overweight” rating in a research note on Friday, May 3rd. Finally, Argus lifted their target price on Hologic from $89.00 to $95.00 and gave the company a “buy” rating in a research note on Thursday, May 9th. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $85.55.

Hologic Trading Up 0.5 %

HOLX stock traded up $0.43 during midday trading on Wednesday, hitting $78.89. 2,177,364 shares of the company’s stock were exchanged, compared to its average volume of 1,623,342. The stock’s fifty day moving average price is $74.16 and its 200-day moving average price is $74.72. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97. The company has a market cap of $18.41 billion, a PE ratio of 40.25, a price-to-earnings-growth ratio of 2.58 and a beta of 0.99. Hologic, Inc. has a one year low of $64.02 and a one year high of $82.45.

Hologic (NASDAQ:HOLX) last posted its earnings results on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share for the quarter, topping the consensus estimate of $0.98 by $0.05. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company’s revenue for the quarter was down .8% on a year-over-year basis. During the same period in the previous year, the company posted $1.06 earnings per share. Research analysts predict that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.